相关实验视频
Updated: Jul 15, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.8K
氧黄A通过调节miR-9a-5p/SRC轴来抑制大鼠血小板的过激活
Wei Huang1, Wendong Yao1, Yayun Weng1
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China.
Archives of biochemistry and biophysics
|September 25, 2023
概括
水氧沙黄A (HSYA) 通过上调 miR-9a-5p 来抑制病态血小板激活,抑制 SRC/ERK1/2 途径. 这减少了血小板聚合,为心血管疾病治疗提供了潜在的可能性.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 病理性血小板激活是心血管疾病的关键因素.
- 氧黄A (HSYA) 具有抗血小板作用,但其机制尚不清楚.
研究的目的:
- 阐明HSYA抑制血小板激活和聚合的机制.
- 研究SRC/MAPK通路和miR-9a-5p在HSYA抗血小板作用中的作用.
主要方法:
- 血小板激活测定,糖蛋白表达分析,流量测量和体内小鼠研究.
- 转录组分析,miRNA分析,生物信息学,双露西法酶记者测定和细胞转染实验.
- 研究了SRC/PLCγ2/PKCδ/MEK/ERK1/2信号通路和miR-9a-5p调节.
主要成果:
- HSYA抑制了血小板表面糖蛋白IIβ/IIIα的表达,血栓素A2 (TXA2) 的产生和Ca2+的积累.
- 在大鼠中,HSYA抑制了SRC和MAPK3 (ERK1/2) 基因表达,并降低了血小板过聚.
- 在HSYA上调节了针对SRC的miR-9a-5p,从而抑制了SRC/PLCγ2/PKCδ/MEK/ERK1/2通路.
结论:
- HSYA通过上调 miR-9a-5p 发挥抗血小板作用,这抑制了 SRC/PLCγ2/PKCδ/MEK/ERK1/2 信号轴.
- 这种机制导致血小板激活和聚合减少,突出显示HSYA对心血管疾病的治疗潜力.
相关概念视频
01:22Formation of the Platelet Plug
6.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552